Canadian Centre on Substance Use and Addiction

Canadian Centre on Substance Use and Addiction
Saffron Blaze · CC BY-SA 3.0 · source
Name	Canadian Centre on Substance Use and Addiction
Type	Crown corporation
Founded	1988 (as Canadian Centre on Substance Abuse); 2017 (renamed)
Headquarters	Ottawa, Ontario
Area served	Canada

Contents

Canadian Centre on Substance Use and Addiction is a federal crown corporation established to provide national leadership on substance use, addiction and related harms across Canada. The organization evolved from policy and public health developments involving institutions such as Health Canada, Public Health Agency of Canada, Canadian Institutes of Health Research, and provincial counterparts including Ontario Ministry of Health and Alberta Health Services. It operates within a milieu shaped by legislation and events including the Controlled Drugs and Substances Act, the Opioid crisis in Canada, the HIV/AIDS epidemic in Canada, and shifts in policy exemplified by the legalization of Cannabis in Canada.

History

The entity originated in 1988 amid efforts paralleling the work of the World Health Organization, United Nations Office on Drugs and Crime, and national agencies such as Statistics Canada and Correctional Service of Canada. Early decades saw collaboration with research funders like the Canadian Institutes of Health Research and public health actors including the Public Health Agency of Canada and the Canadian Paediatric Society. Major milestones include responses to the Fentanyl epidemic, engagement during the SARS outbreak era of public health modernization, and the 2017 rebranding that reflected influences from organizations such as the Canadian Centre for Occupational Health and Safety and policy reviews by the Parliament of Canada. Historical partnerships and reports connected the organization to provincial bodies like British Columbia Ministry of Health, academic centres such as the University of Toronto and McGill University, and advocacy groups including the Canadian Drug Policy Coalition and Centre for Addiction and Mental Health.

The mandate derives from federal statutes and policy priorities articulated by the House of Commons of Canada, the Senate of Canada and ministers formerly holding portfolios at Health Canada and the Department of Justice (Canada). Objectives emphasize evidence synthesis with institutions like National Institutes of Health, guideline development akin to work by the National Institute for Health and Care Excellence, and knowledge translation engaging stakeholders including the Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, and professional bodies such as the Canadian Nurses Association and Canadian Pharmacists Association.

Governance involves a board of directors appointed through processes tied to central agencies such as the Treasury Board of Canada Secretariat, with oversight comparable to other crown corporations like Canada Revenue Agency in accountability frameworks. Funding streams include federal appropriations from Parliament of Canada, competitive grants from bodies like the Canadian Institutes of Health Research, and contracts with provincial ministries such as the Ministry of Health and Long-Term Care (Ontario). The centre’s governance interactions have involved auditors and watchdogs including the Office of the Auditor General of Canada and parliamentary committees such as the Standing Committee on Health.

Programs align with national responses to the Opioid crisis in Canada, harm reduction models promoted by groups like the Vancouver Coastal Health and evidence-based interventions informed by research at institutions such as Simon Fraser University and University of British Columbia. Initiatives include knowledge mobilization similar to that of the Canadian Patient Safety Institute, development of guidelines analogous to those from the Canadian Task Force on Preventive Health Care, and training collaborations involving professional colleges like the Royal College of Physicians and Surgeons of Canada and the Canadian Centre for Occupational Health and Safety. The centre has supported projects on safer supply, supervised consumption inspired by programs in Vancouver and Toronto, and surveillance systems paralleling work by Statistics Canada and the Public Health Agency of Canada.

Research outputs include evidence reviews, guideline documents, and surveillance reports produced in concert with academic partners such as McMaster University, Queen's University, Dalhousie University, and think tanks like the Fraser Institute and Canadian Institute for Health Information. Publications have addressed topics tied to the Fentanyl epidemic, medication-assisted treatment models exemplified by buprenorphine implementation studies, and the public health implications of policy shifts such as Cannabis in Canada. Reports have been cited in parliamentary hearings, legal proceedings involving the Supreme Court of Canada, and provincial reviews by entities such as the Ontario Health Quality Council.

The centre maintains partnerships across a broad network including federal agencies like Health Canada and the Public Health Agency of Canada, provincial health authorities such as Alberta Health Services and Vancouver Coastal Health, academic institutions including University of Ottawa and McGill University, and community organizations like the Canadian Drug Policy Coalition and Mothers Against Drunk Driving. Engagement extends to international cooperation with the World Health Organization, the Pan American Health Organization, and the United Nations Office on Drugs and Crime, as well as collaboration with professional organizations including the Canadian Medical Association, Canadian Psychiatric Association, and patient advocacy groups.

Critiques have arisen in contexts involving harm reduction policies, with debate among stakeholders such as provincial governments (e.g., Ontario Ministry of Health), advocacy organizations like the Canadian Centre for Policy Alternatives, and clinical groups similar to the College of Physicians and Surgeons of Ontario. Controversial topics have included positions on supervised consumption services modeled in Vancouver and Insite, guidance during the Opioid crisis in Canada, perceived conflicts related to funding partnerships with entities linked to pharmaceutical policy debates involving companies scrutinized by the Competition Bureau (Canada), and tensions highlighted in parliamentary reviews by the Standing Committee on Health and audits by the Office of the Auditor General of Canada.

Category:Health organizations based in Canada Category:Addiction organizations Category:Crown corporations of Canada